Patent

Information about the patent

An US patent has been granted (No US 9,572,862,B2) on February 21, 2017. WIPO (World Intellectual Property Organization) / PCT (Patent Cooperation Treaty) No. WO 2013/149259 A1.

The invention provides methods for treating obesity in a subject comprising administrating an effective amount of CST or its equivalent to a subject afflicted with obesity so as to maintain an effective amount of circulating CST in the subject to promote lipolysis and oxidation of released fatty acids in both liver and adipose tissue, thereby, reducing adipose tissue weight and hence treating obesity in the afflicted subject.

Advancement in the invention

Subsequent work on CST by the inventors extended the application of CST and its equivalents, RI-CST (Retro-Inverso CST peptide which is a stable analog, resistant to cleavage by internal proteases) and NSC-177941( a small organic molecule, not a peptide) to control blood sugar and inflammation in obese and diabetic models. These results are published in a scientific journal.